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Objectives. To investigate which rheumatoid arthritis (RA) disease activity measures are being collected in patients receiving
glucocorticoids,non-biologicorbiologicdisease-modifyingantirheumaticdrugs (DMARDs)inAustralianrheumatologypractice.
Methods. A retrospective audit of medical records was conducted from eight rheumatology practices around Australia. Each
rheumatologist recruited 30 consecutive eligible patients into the review, 10 of whom must have been receiving a biological
agent for rheumatoid arthritis. Disease activity measures and radiographic assessments were collected from each patient’s last
consultation. For biologic patients, disease activity measures were also collected from when the patient was ﬁrst initiated on the
biologicalagent. Results. At last consultation,the disease measures that were recorded most often were ESR (89.2%), haemoglobin
(87.5%),and CRP (84.2%).DAS28 wasinfrequently recorded (16.3%).The rate of recording diseaseactivity measures forpatients
receiving biologic DMARDs decreased over time (mean 27 months). Conclusion. This review has shown inconsistency of RA
activity measures being recorded in Australian rheumatology clinical practice. An accurate assessment of the disease process is
necessary to eﬀectively target rheumatoid arthritis patients to treat in order to achieve optimal outcomes.
1.Introduction
Rheumatoid arthritis (RA) is a chronic systemic inﬂamma-
tory autoimmune disease that has a highly variable presen-
tation and time course. The symptoms and signs of RA may
vary from joint complaints, such as pain, stiﬀness, swelling
to functional impairment, fatigue, and loss of general health
[1]. Importantly, persistently high disease activity can lead
to irreversible joint damage [2], disability [3], and even a
reduction in life expectancy [4]. Quantitative assessment of
RA diﬀers from many other clinical conditions in that a
single “gold standard” measure, which can be used to assess
all patients, is not available for the diagnosis, prognosis, or
monitoring of RA.
Disease activity measures are useful in RA as they reﬂect
patient outcome and response to therapy in clinical care and
in clinical trials. Various measures exist to provide informa-
tion aboutthe various dimensions ofoutcomes,for example,
pain, disability,and impairment. However,duetodiﬀerences
in disease expression of RA,many disease measures havelim-
itations, for example, joint counts have poor reproducibility;
the erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) are poor diagnostic measures as they are
normal in 40% of patients with RA; radiographs change
slowly, reﬂecting cumulativedamage rather than acting as an
early-stage diagnostic test [5].
In order to standardise the assessment of RA in clinical
trials of antirheumatic agents, in 1993, the American College
of Rheumatology (ACR) recommended core sets of disease
activity variables to be measured [6, 7]. These include 7 core
measures: swollen joint count, tender joint count, patient
assessment of global status, an acute phase reactant (ESR or
CRP), and health professional assessment of global status,
physical function, and pain. However, use ofthe ACRcriteria
is limited by the fact that they provide relative measure of
response and cannot be used to describe a patient’s disease
activity at a speciﬁc point in time or to compare disease
activity states between individual patients or cohorts of2 ISRN Rheumatology
patients [8]. For these reasons, indices that allow continuous
measures of disease activity have also been developed.
In 2008, the European League Against Rheumatism
(EULAR), together with the ACR, developed guidelines for
response criteria based on the Disease Activity Score (DAS)
and the modiﬁed DAS score—DAS28 [9]. These scores,
which are composed of four measures (tender joint count,
swollen joint count, acute phase reactant laboratory test, and
patient estimate of global status), allow changes in RA status
to be determined and have recently been validated for use
in RA clinical trials [10]. These disease measures and ACR
response criteria have shown comparable performance and
validity in RA studies [9–11].
WiththearrivalofnewtherapeuticoptionsinRA,suchas
biological agents, remission is now considered to be the ulti-
mate goal of treatment. Deﬁning treatment targets can help
facilitate treatment changes to occur within distinct time-
frames according to deﬁned algorithms [12, 13]. This con-
cept of “treating to target” has been widely adopted in prac-
tice for many diseases including diabetes, hyperlipidaemia,
and hypertension. Treating RA strategically according to
deﬁned outcome targets leads to signiﬁcantly better clinical
outcomes than traditional means of followup [12]. Recently,
an international task force (T2T) recommended regular
follow-up every 1 to 3 months during active disease with
appropriate therapeutic adaptation to reach either remission
in early disease or low disease activity in long-standing dis-
ease within 3 to 6 months [14]. Itis recommended that a val-
idated composite measure of disease activity, which includes
frequent joint assessment and imaging should be used in
routine clinical practice to guide treatment decisions [13].
Due to the diﬃculty in applying the ACR criteria for
remissioninclinicaltrials[8],manytrialshaveusedtheDAS-
based deﬁnitions. In a recent randomised trial, both DAS
and DAS28 remission results were found to be comparable
for assessing, achieving, and sustaining remission in RA.
Therefore,itisimportant forphysicians tochoosethecorrect
outcome measures and indices that can be used in clinical
practice to assess treatment eﬀectiveness and remission. In
the clinical practice setting, however, little attention and
guidance have been given about what to monitor, which
assessments to use, and how to deﬁne response and remis-
sion of RA [1]. The Australian Rheumatology Association
recommends using DAS28 to monitor patients receiving a
biological agent in clinical practice [12]. In Australia, the
Pharmaceutical Beneﬁts Scheme (PBS) requires an assess-
ment of treatment response based on ESR, CRP, or active
joint count for the prescription of reimbursable biologi-
caldisease-modifying antirheumatic drugs(bDMARD)[15].
There may be little time during consultations to perform
a detailed evaluation, such as the ACR core criteria, for
every patient. Consequently, standard rheumatology care
may be delivered largely based on qualitative impressions
ratherthanquantitativedatacollection[5],leadingtodispar-
ities in the assessment of RA activity between rheumatology
practices.
The aim of this Australian quality assurance review was
to investigate which RA disease measures are being collected
in conventional rheumatology practice and what diﬀerences
may exist in these measures for patients receiving biolog-
ical therapy, compared with patients receiving steroids or
DMARDs. This was conducted via a retrospective audit of
patient medical records.
2.Methods
2.1. Rheumatology Practices and Patients. A total of eight
rheumatologists, from NewSouthWales, Queensland, Victo-
ria, and Western Australia participated in this observational,
nonrandomised, pilot quality assurance review between
December 2008 and February 2009. The patient population
reviewed represented a cross-sectional cohort of patients
in predominantly private practice. Each rheumatologist
recruited 30 consecutive eligible patients into the review
by retrospectively reviewing the medical records of those
patients who visited their practice for consultation as of 1
April 2008. Ten of the 30 patients must have been receiving
a biological agent for RA (classiﬁed as “biologic patients”)
at the time of the audit while the remaining 20 patients
must have been receiving a nonbiological agent for RA
(e.g., steroids and/or DMARD; classiﬁed as “nonbiologic
patients”), with no previous history of biological use. Patient
privacy was maintained throughout the review using non-
identiﬁable patient ID numbers. The review was conducted
in accordance with the recommendations of the Australian
National Health and Medical Research Council (NHMRC)
[14]. The NHMRC states that a quality assurance review
can proceed without review by a Human Research Ethics
Committee as long as patient consent has been obtained,
privacyismaintained, andpatientswill notsuﬀeranyburden
or harm.
2.2. Data Collection. Data were collated and analysed by
the independent audit administrator, Discovery Sydney,
Walsh Bay, NSW. The primary objectives of the audit
were to assess which RA disease measurements are being
collectedinroutineclinicalpracticeandhowfrequentlythese
measures are taken via retrospective analyses of patient data
records. The secondary objective was to investigate whether
data collection varies between those patients treated with
DMARDs and bDMARDs.
Rheumatologistsdocumentedeachpatient’sdemograph-
ics and medical history by referring to the patient’s medical
records. This included age, sex, and the type and number of
treatments, including steroids and DMARDs. The following
disease activity measures were recorded from each patient’s
last consultation: swollen joint count, tender joint count,
CRP, ESR, morning stiﬀness, haemoglobin, rheumatoid
factor(RF),diseaseactivityscore28(DAS28),physician’sand
patient’s global assessment of disease activity, Health Assess-
ment Questionnaire—Disability Index (HAQ-DI), and any
other standard measures that may have been used by the
rheumatologist (e.g., Simpliﬁed Disease Activity Index).
Radiographic assessments were also audited. For biologic
patients, in addition to recording these disease measures at
their last consultation, they were also recorded from when
the patient was ﬁrst initiated on the biological agent.ISRN Rheumatology 3
Table 1: Patient demographics and treatments.
All patients
(n = 240)
Biologic patients
(n = 80)
Nonbiologic patients
(n = 160)
Mean age, years (range) 58.6 (15–85) 55.4 (15–82) 60.2 (23–85)
Female (%) 70 75 68
Receiving a steroid at last consultation(%) 51.7 51.3 51.9
Receiving a DMARD at last consultation(%) 92.1 83.8 96.3
Number of DMARDs prescribed (%)
Zero 7.9 16.3 3.8
One 56.3 66.3 51.3
Two 29.2 15.0 36.3
Three 6.7 2.5 8.8
Type of DMARD (%)
Methotrexate 79.2 75.0 81.3
Leﬂunomide 29.6 13.8 37.5
Hydroxychloroquine 13.8 8.8 16.3
Sulfasalazine 9.2 5.0 11.3
Other (azathioprine,6mercaptopurine, cyclosporine) 2.9 1.3 3.8
2.3. Statistical Analyses. Results for disease measure record-
ing were reported as percentages. Statistical analysis on
the frequency of recording a particular RA disease activity
measure (including radiographic data) between biologic and
nonbiologic patients was done using a Chi-squared test with
one degree of freedom. A Mc Nemar’s test with one degree
of freedom was used to evaluate any signiﬁcant diﬀerence
between the frequencies of recording a particular RA activity
measure at the initiation of a biologic compared with the
patient’s last consultation. Mean ± standard errors (SE) were
calculated for drug doses, and a Kruskal-Wallis rank sum
test with one degree of freedom was used to evaluate any
signiﬁcant diﬀerence between doses prescribed to biologic
and nonbiologic patients. A P-value <. 05 was considered
signiﬁcant.
3.Results
3.1. Patient Demographics and Treatments. The patient dem-
ographics and current treatments of all enrolled patients
(n = 240) are shown in Table 1.T h em e a np a t i e n ta g e
was 58.6 years (standard deviation 13.4; range 15–85 years),
and reﬂective of the general RA population in that a higher
proportion of patients enrolled were female (70%). In terms
of treatments, more biologic patients received a steroid
(prednisolone) at some point in their management plan
for RA compared with nonbiologic patients (90.0% versus
80.0%, resp.). However, the percentage of patients receiving
prednisolone at their last consultation was similar between
the two groups (51.3% versus 51.9%, resp.). The mean
prednisolone dose for all patients was 5.77 ± 0.27mg/day;
there was no signiﬁcant diﬀerence in dose between biologic
and nonbiologic patients (6.35 ± 0.5mg/day versus 5.72 ±
0.31mg/day; P = .9054). A high proportion of biologic
and nonbiologic patients were receiving treatment with
a DMARD (83.8% and 96.3%, resp.) at their last consulta-
tion. Over half of all patients were receiving one DMARD,
the most common being methotrexate (79.2%; mean dose
16.2 ± 0.41mg/day). As per protocol, all biologic patients
were receiving a biologic treatment at their last consultation
and no nonbiologic patient had previously received a bi-
ological agent.
3.2. Disease Measures. A summary of the RA measures re-
ported in all patients, nonbiologic patients, and biologic
patients is shown in Figure 1. At the patients’ last con-
sultation, the disease measures that were recorded most
often for the overall patient population were ESR (89.2%),
haemoglobin (87.5%), and CRP (84.2%). Swollen joint
counts and tender joint counts were documented in the
medical records of approximately half of all patients enrolled
(53.8% for both measures) while RF was reported for
approximately a third of all patients (30.8%). DAS28
(16.3%), morning stiﬀness (13.3%), and the patient’s global
assessment of disease activity (11.3%) were recorded infre-
quently. The physician’s global assessment of disease activity
was very rarely measured (0.4%), and HAQDI was never
taken. No other RA activity measures or indices were
documented.
3.3. Biologic versus Nonbiologic Patients. Among nonbiologic
patients, the only measures that were documented in more
than 90% of patients were haemoglobin (95.6%) and ESR
(94.4%). In comparison, the documentation of these two
measures for biologic patients occurred signiﬁcantly less
frequently: 71.3% (P<. 0001) and 78.8% (P<. 001), respec-
tively. Swollen and tender joint counts were occasionally
recorded in nonbiologic patients (48.8% for both measures)
while in biologic patients these measures were recorded
signiﬁcantly more often (63.8% for both measures; P<. 05).4 ISRN Rheumatology
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Figure 1: Frequency of RA disease measure recording for all patients, nonbiologic patients, and biologic patients at their last consultation.
Statistical signiﬁcance between nonbiologic and biologic patients (Chi-squared test, 1 degree of freedom): ∗∗∗P<. 0001; ∗∗P<. 001;
∗P<. 05; NS: not signiﬁcant.
RF was measured in approximately half of all nonbiologic
patients (42.5%) while in biologic patients it was docu-
mented signiﬁcantly less often (7.5%; P<. 0001). Morn-
ing stiﬀness was documented signiﬁcantly more often for
nonbiologic patients than biologic patients (18.1% versus
3.8%; P<. 05). No signiﬁcant diﬀerence was seen between
nonbiologic and biologic patients in the recording of CRP,
DAS28, patient’s global assessment of disease activity, physi-
cian’s assessment of disease activity, or HAQ-DI.
3.4. Biologic at Initiation versus Last Visit. The mean period
of time from a patient being initiated on a biologic to
last consultation was 27 months. The change in RA disease
measure recording between initiation of a biologic and
last consultation is shown in Figure 2. At the initiation
of a biologic, the ﬁve disease measures of swollen joint
count (92.5%), tender joint count (90.0%), ESR (88.8%),
CRP (88.8%), and haemoglobin (82.5%) were frequently
recorded. RF was occasionally taken at initiation (45%
of patients) while DAS28, patient’s global assessment of
disease activity, morning stiﬀness, and HAQ-DI score were
all recorded infrequently (≤22.5%). The physician’s global
assessment of disease activity was never taken. In gen-
eral, the frequency that these measurements were recorded
decreased over time. At the patients’ last consultation,
only CRP was regularly assessed at consultation (80% of
patients). Measures of swollen joint count and tender joint
count were both signiﬁcantly reduced to an incidence of
63.8% (P<. 0001), compared with approximately 90%
when the patient’s biologic was initiated. The documenta-
tion of haemoglobin was also signiﬁcantly reduced (82.5%
versus 71.3%; P<. 05) while RF showed the largest
signiﬁcant drop in recording with a decrease from 45%
at initiation to 7.5% at last consultation (P<. 0001).
ESR, CRP, patient’s global assessment of disease activity,
DAS28, morning stiﬀness, and HAQ-DI were all reduced
compared with initiation, although these reductions were
not statistically signiﬁcant. The physician’s global assess-
ment of disease activity was never taken at the patient’s last
visit.
3.5. Radiographic Data. The proportion of patients with
radiographic data available in their medical records was
similar between biologic (70.0%) and nonbiologic patients
(76.9%). The most common radiographic method for both
groups was the use of X-ray (91.1% biologic, 89.4% nonbio-
logic; P = NS). CT scans and ultrasound images were used
rarelyforboththebiologicandnonbiologicgroups(CTscan:
8.9% biologic versus 8.1% nonbiologic; ultrasound: 7.1%
biologic versus 8.1% nonbiologic; both comparators P =
NS). MRI data were taken more often for biologic patients
than nonbiologic patients (23.2% versus 17.1%, resp.),
althoughthisdiﬀerencewasnotsigniﬁcant. Ofthose patients
with radiographic data in their records, approximately one
in ﬁve nonbiologic patients had evidence of erosive disease
(22.8%) and/or disease progression (17.9%). Signiﬁcantly
more biologic patients had documented evidence of erosive
disease (41.1%;P<. 05)comparedwith nonbiologicpatients
(22.8%).Althoughthedocumentationofdisease progression
was also higher in biologic patients (30.4%) compared
with nonbiologic patients (17.9%), this ﬁnding was not
signiﬁcant.ISRN Rheumatology 5
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Figure 2: Frequency of RA disease measure recording for biologic patients at the initiation of a biologic and at their last consultation.
Statistical signiﬁcance between nonbiologic and biologic patients (McNemar’s test, 1 degree of freedom): ∗∗∗P<. 0001; ∗P<. 05; NS: not
signiﬁcant.
4.Discussion
It has been traditional in clinical practice to monitor disease
status as well as the eﬃcacy and toxicity from therapy with
individual outcome measures in RA. Guidelines exist that
recommend outcome measures for clinical trials in RA, but,
until recently, there were no formal guidelines to advise
rheumatologists on which disease activity measures should
be regularly monitored in daily clinical practice. Certain
measures are only required to be recorded in order to
fulﬁl the PBS requirements for bDMARD initiation and
continuation. However individual measures do not fully
reﬂect the complex reality of RA disease activity, hence the
development of composite indices, such as the ACR criteria,
DAS, and DAS28 [16]. The Australian Rheumatology Asso-
ciation encourages rheumatologists to record DAS28 at each
visit [14].
The aim of this observational, nonrandomised, quality
assurance review was to gain knowledge on which measures
are being collected in Australian rheumatology practice by
retrospectivelyreviewingthemedicalrecordsofpatientswith
RA. The results of this review show that RA disease activity
measures are not only used infrequently but that there is
a lack of consistency with which RA disease measures are
recorded in rheumatology clinical practice within Australia.
The low recording of RA disease measures observed in this
quality assurance review has been mirrored in other studies
within Australia and the rest of the world, which have
shown that many of the measures used in clinical trials are
infrequently used in clinical practice [17–20]. In addition, to
ourknowledge,thisistheﬁrstr eviewtoshowthatdiﬀerences
exist in the number and types of RA disease measures that
are captured for patients receiving biological treatments,
compared with steroids or DMARDS, and that this rate of
recording disease measures for biologic patients decreases
over time, from when a patient was initiated on a biological
agent to their last consultation.
Severaltrials, theTight Control forRheumatoidArthritis
(TICORA), BeSt, and the Computer-Assisted Management
for Early Rheumatoid Arthritis (CAMERA) studies [21–23],
have shown the beneﬁcial eﬀect of a tight control strategy
in the treatment of RA. Notably, the TICORA study has
shown that a strategy of intensive outpatient management
of RA, using DAS28 scores as a guide, can signiﬁcantly
improve disease activity. Radiographic disease progression,
physical function, and quality of life were also shown to
be improved [22]. In addition, the use of this validated
composite score may enhance communication and unifor-
mity between health professionals and the quality of care
provided [24]. An international task force has published
guidelines recommending treatment to target by measuring
diseaseactivityandadjustingtherapyaccordinglytooptimise
outcomes in rheumatoid arthritis [13]. It is recommended
that validated composite measures of disease activity, which
include joint assessments, be obtained and documented
regularly in routine clinical practice to guide treatment deci-
sions. However, in this current review, the most commonly
used composite measure of disease activity, the DAS28, was
rarely recorded for either biologic or nonbiologic patients.
Althoughthese ﬁndings are important, the limitations of
this review must be noted. Firstly, the data are from a small
subset of rheumatologists who were not chosen at random,6 ISRN Rheumatology
but who were invited to participate. As a consequence, the
patient population reviewed represented a cross-sectional
cohort of patients in predominantly private practice. Sec-
ondly, since the review was nonrandomised and observa-
tional in nature, it relied on rheumatologists returning data
in a nonbiased and accurate manner. Finally, the review
assumed that rheumatologists conduct a set of RA activity
measurements at every patient consultation, which may not
always be the case.
Nevertheless,ourﬁndings doraiseanumberofquestions
about the management of patients with RA in Australian
rheumatology practice. Notably, are patients having their
disease monitored appropriately in order to assess disease
activity, remission, and progression, and consequently, are
optimal treatments being chosen to control their disease? A
number of reasons as towhy these outcomemeasures are not
being measured and recorded regularly at each consultation
may exist. Possible barriers to regular monitoring may
include lack of time and support staﬀ during consultations,
unfamiliarity with scores and diﬃculty with their interpre-
tation, belief that nonlaboratory data are “soft” assessment
tools, and the fear of annoying patients with measurements
[25].The resultsobservedmay also bea consequenceofpoor
medical record keeping. High-quality medical record keep-
ing, containing detailed data on the patient and RA status, is
essential to provide optimal patient care and assist in sharing
information among healthcare professionals [26]. Further
investigationsintothecharacteristicsofrheumatologistswho
perform RA measures frequently, compared with those who
do not, are necessary to elucidate the exact reasons for these
barriers.
In conclusion, this quality assurance review has shown
an apparent lack of consistent RA activity measures being
recorded in Australian rheumatology clinical practice. With
the advent of bDMARDs and the demonstrated beneﬁt
of tight disease control [22], an accurate assessment of
the disease process is necessary to treat patients with RA
eﬀectively. Index scores, such as DAS28, are a practical and
easy to perform clinical-based method, and, unlike the ACR
criteria, DAS28 allows individual responses to therapy to be
assessed. Nevertheless, their use may need further guide-
line recommendations and appropriate education before
they become embedded in routine rheumatology clinical
practice.
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